Pharmacology of Corticosteroids for Diabetic Macular Edema
نویسندگان
چکیده
منابع مشابه
Pharmacology of Corticosteroids for Diabetic Macular Edema.
Purpose Corticosteroids remain the mainstay of treatment for inflammatory diseases almost 80 years after their first clinical use. Topical ophthalmic formulations of corticosteroids have been available to treat disease of the anterior segment of the eye, but the approval of corticosteroids to treat vitreoretinal diseases, including vein occlusion, diabetic macular edema, and uveitis, has occurr...
متن کاملUpdate on corticosteroids for diabetic macular edema
Diabetic macular edema (DME) remains an important cause of visual loss. Although anti-vascular endothelial growth factor (VEGF) agents are generally used as first-line treatments for patients with center-involving DME, there is an important role for corticosteroids as well. Corticosteroids may be especially useful in pseudophakic patients poorly responsive to anti-VEGF therapies, in patients wi...
متن کاملIntravitreal Corticosteroids in Diabetic Macular Edema
Purpose: To review the relationship between kinetics, efficacy, and safety of several corticosteroid formulations for the treatment of diabetic macular edema. Methods: Reports of corticosteroid use for the treatment of diabetic macular edema were identified by a literature search, which focused on the pharmacokinetics, efficacy, and safety of these agents in preclinical animal models and clinic...
متن کاملRemote Ischemic Preconditioning and Diabetic Macular Edema
Objective: Remote Ischemic Preconditioning (RIPC) as the transient ischemia and reperfusion of the arm is a promising method for protecting different tissue from future ischemia. These effects might be mediated through vascular and endothelial growth factor (VEGF) pathway. We investigated the influence of RIPC on diabetic macular edema (DME) as a chronic ischemic condition in patients who were ...
متن کاملDiabetic Macular Edema
Introduction Over the last one decade the management of diabetic macular edema has undergone a paradigm change. This is attributed to the newer diagnostic tests and pharmacological agents. There are enough good randomized controlled trials to prove the efficacy of these drugs. However, in clinical practice, there are many situations where the application of the findings of these clinical trials...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Investigative Opthalmology & Visual Science
سال: 2018
ISSN: 1552-5783
DOI: 10.1167/iovs.17-22259